Sorrento Announced Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
On Jul. 20, 2020, Sorrento announced that its partner Mabpharm had received approval of its New Drug Application…
-
-
Amgen acquired worldwide rights to psoriasis drug Otezla (apremilast) For $13.4 Billion
On Aug. 26, 2019, Amgen acquired worldwide rights to Otezla (apremilast), the only oral, non-biologic treatment for psoriasis…
